Terapia antirretroviral baseada em dolutegravir 1 vez/dia em bebês e crianças vivendo com HIV a partir de 4 semanas de idade: resultados da coorte abaixo de 14 kg do estudo randomizado ODYSSEY.

Once-daily dolutegravir-based antiretroviral therapy in infants and children living with HIV from age 4 weeks: results from the below 14 kg cohort in the randomised ODYSSEY trial – The Lancet HIV

Comentário no Twitter

New: Once-daily dolutegravir-based antiretroviral therapy in infants and children living with HIV from age 4 weeks: results from the below 14 kg cohort in the randomised ODYSSEY trial by Pauline Amuge @bayloruganda and colleagues @MRCCTU https://t.co/mc1jWSXMU2 #openaccess pic.twitter.com/A10LgZcwjF

— The Lancet HIV (@TheLancetHIV) September 1, 2022